BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28070995)

  • 1. Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity.
    Nie XY; Li JL; Zhang Y; Xu Y; Yang XL; Fu Y; Liang GK; Lu Y; Liu J; Shi LW
    J Zhejiang Univ Sci B; 2017 Jan.; 18(1):37-47. PubMed ID: 28070995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions.
    Rudez G; Bouman HJ; van Werkum JW; Leebeek FW; Kruit A; Ruven HJ; ten Berg JM; de Maat MP; Hackeng CM
    Circ Cardiovasc Genet; 2009 Oct; 2(5):515-21. PubMed ID: 20031628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.
    Liu J; Nie XY; Zhang Y; Lu Y; Shi LW; Wang WM
    Chin Med J (Engl); 2015 Aug; 128(16):2183-8. PubMed ID: 26265611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.
    Tang N; Yin S; Sun Z; Xu X; Qin J
    Scand J Clin Lab Invest; 2015 May; 75(3):223-9. PubMed ID: 25594796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome.
    Liu X; Luo Y; Lai Y; Yao Y; Li J; Wang Y; Zheng SL; Xu J; Liu X
    J Genet; 2016 Jun; 95(2):231-7. PubMed ID: 27350664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.
    Liu R; Zhou ZY; Chen YB; Li JL; Yu WB; Chen XM; Zhao M; Zhao YQ; Cai YF; Jin J; Huang M
    Acta Pharmacol Sin; 2016 Jul; 37(7):882-8. PubMed ID: 27133299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel.
    Yang HH; Chen Y; Gao CY
    Cardiovasc Ther; 2016 Dec; 34(6):460-467. PubMed ID: 27566695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.
    Tam CC; Kwok J; Wong A; Yung A; Shea C; Kong SL; Tang WH; Siu D; Chan R; Lee S
    J Int Med Res; 2017 Feb; 45(1):134-146. PubMed ID: 28222641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Association of ITGB3, P2RY12, and CYP2C19 gene polymorphisms with platelet functional activity in patients with coronary heart disease during dual antiplatelet therapy].
    Muslimova EF; Afanasiev SA; Rebrova TY; Sergienko TN; Repin AN
    Ter Arkh; 2017; 89(5):74-78. PubMed ID: 28631703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade.
    Bonello L; Camoin-Jau L; Mancini J; Bessereau J; Grosdidier C; Alessi MC; Ostorero M; Dignat-George F; Paganelli F
    Thromb Res; 2012 Jul; 130(1):70-4. PubMed ID: 22285300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS.
    Peng L; Liu J; Qin L; Liu J; Xi S; Lu C; Yin T
    Thromb Res; 2017 Sep; 157():97-102. PubMed ID: 28734158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of clopidogrel high on-treatment reactivity with clinical outcomes and gene polymorphism in acute ischemic stroke patients: An observational study.
    Fu H; Hu P; Ma C; Peng F; He Z
    Medicine (Baltimore); 2020 Apr; 99(15):e19472. PubMed ID: 32282698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness.
    Ou W; He Y; Li A; Liu B; Jin L
    Int Heart J; 2016 Sep; 57(5):586-92. PubMed ID: 27488401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome.
    Collet JP; Kerneis M; Hulot JS; O'Connor SA; Silvain J; Mansencal N; Brugier D; Abtan J; Barthélémy O; Vignalou JB; Payot L; Rousseau H; Vicaut E; Montalescot G;
    Thromb Haemost; 2016 Jan; 115(2):382-91. PubMed ID: 26423110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.
    Nagashima Z; Tsukahara K; Morita S; Endo T; Sugano T; Hibi K; Himeno H; Fukui K; Umemura S; Kimura K
    J Cardiol; 2013 Sep; 62(3):158-64. PubMed ID: 23886632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
    Namazi S; Kojuri J; Khalili A; Azarpira N
    Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
    Mărginean A; Bănescu C; Moldovan V; Scridon A; Mărginean M; Bălaşa R; Maier S; Ţăruşi M; Dobreanu M
    Clin Appl Thromb Hemost; 2017 Apr; 23(3):255-265. PubMed ID: 26873108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.
    Sridharan K; Kataria R; Tolani D; Bendkhale S; Gogtay NJ; Thatte UM
    Indian J Pharmacol; 2016; 48(4):350-354. PubMed ID: 27756942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.